

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/P8C0368C4EBEN.html>

Date: December 2019

Pages: 51

Price: US\$ 3,500.00 (Single User License)

ID: P8C0368C4EBEN

Abstracts

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019

SUMMARY

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Breast Cancer, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma,

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Sarcomas, Septic Shock, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Ulcerative Colitis and Uveitis.

Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

SupremeCure Pharma Inc

Velacor Therapeutics Pty Ltd

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEL-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones

Featured News & Press Releases

Dec 04, 2019: First two patients enrolled in National Cancer Institute trial of the ability of Lixte Biotechnology's LB-100 to enter recurrent malignant Brain Tumors

Aug 06, 2019: The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings' LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas

Jul 18, 2019: First patient enrolled in phase 1b/2 trial of Lixte Biotechnology's LB-100 in low or intermediate-1 Risk Myelodysplastic Syndrome

Jun 25, 2019: Lixte Biotechnology's PP2A inhibitor, LB-100, improves brain function and motor impairment in a mouse model of Angelman syndrome, a rare human neurodevelopmental disorder

May 16, 2019: PEP-Therapy reports positive results from GLP-Toxicity study of PEP-010 drug candidate

May 15, 2019: Lixte Biotechnology's LB-100 to be evaluated by the National Cancer Institute in a clinical study of LB-100's ability to enter recurrent Glioblastoma Multiforme brain tumors

Nov 05, 2018: FDA approves Lixte Biotechnology's IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 M€ to Develop a Novel Peptide in Oncology

Feb 09, 2018: LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase

Inhibitors

Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering

Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting

Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research

Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
Pipeline by PEP-Therapy SAS, H2 2019
Pipeline by Re-Pharm Ltd, H2 2019
Pipeline by SupremeCure Pharma Inc, H2 2019
Pipeline by Velacor Therapeutics Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

SupremeCure Pharma Inc

Velacor Therapeutics Pty Ltd

I would like to order

Product name: Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/P8C0368C4EBEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8C0368C4EBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970